Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 20Pancreatic Fistula 3Gastroparesis 2Bile Duct Neoplasms 2Recurrence 1Pancreatitis, Chronic 1Pancreatic Ductal Adenocarcinoma 1Non-alcoholic Fatty Liver Disease 1Jaundice, Obstructive 1Hypoxia 1Hemorrhage 1Gastrointestinal Stromal Tumor of Duodenum 1Fatty Liver 1Cholangiocarcinoma 1Carcinoma, Pancreatic Ductal 1

Interventions

Cyclophosphamide 67Dexamethasone 52Peripheral Blood Stem Cell Transplantation 37Lenalidomide 37Rituximab 35fludarabine phosphate 34Bortezomib 30Filgrastim 27Etoposide 27Cytarabine 25Carboplatin 25Busulfan 23Radiotherapy 22Melphalan 22Gemcitabine 22Cyclosporine 21pomalidomide 20fludarabine 20Whole-Body Irradiation 20Mycophenolic Acid 20Paclitaxel 19Methotrexate 18venetoclax 17Cisplatin 17pembrolizumab 16Calcium Dobesilate 16Bevacizumab 16Tacrolimus 14Antilymphocyte Serum 14Nivolumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Recurrence × Pancreaticoduodenectomy × Clear all
NCT04596865 2023-11-18

Recurrence After Whipple's (RAW) Study

University Hospital Plymouth NHS Trust

Completed
1,484 enrolled
Gastrointestinal

Bile Duct Neoplasms, Pancreatic Neoplasms, Recurrence, Cholangiocarcinoma, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡